Bolt Biotherapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 94

Employees

  • Stock Symbol
  • BOLT

Stock Symbol

  • Share Price
  • $1.19
  • (As of Friday Closing)

Bolt Biotherapeutics General Information

Description

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.

Contact Information

Website
www.boltbio.com
Formerly Known As
Bolt Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 900 Chesapeake Drive
  • Redwood City, CA 94063
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bolt Biotherapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.19 $1.14 $0.84 - $2.03 $45.9M 38M 121K -$1.89

Bolt Biotherapeutics Financials Summary

In Thousands,
USD
TTM 30-Sep-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV (64,925) (98,930) (5,268)
Revenue 7,198 5,729 1,260 231
EBITDA (75,621) (88,621) (97,672) (60,316)
Net Income (71,291) (88,098) (98,591) (60,728)
Total Assets 175,355 227,807 307,718 46,542
Total Debt 20,857 22,611 24,355 10,877
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Bolt Biotherapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bolt Biotherapeutics‘s full profile, request access.

Request a free trial

Bolt Biotherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Bolt Biotherapeutics‘s full profile, request access.

Request a free trial

Bolt Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that lev
Drug Discovery
Redwood City, CA
94 As of 2022
00000
0000 0000-00-00
00000000 00000

000000

it amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore
0000000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000

000000

exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute
0000000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bolt Biotherapeutics Competitors (31)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
Nkarta Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
ORIC Pharmaceuticals Formerly VC-backed South San Francisco, CA 00 00000 000000000 00000
Aura Biosciences Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
You’re viewing 5 of 31 competitors. Get the full list »

Bolt Biotherapeutics Patents

Bolt Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022300383-A1 Bis-benzimidazole sting agonist immunoconjugates, and uses thereof Pending 25-Jun-2021 00000000000
CA-3222082-A1 Bis-benzimidazole sting agonist immunoconjugates, and uses thereof Pending 25-Jun-2021 00000000000
AU-2022245340-A1 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof Pending 26-Mar-2021 00000000000
CA-3212926-A1 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof Pending 26-Mar-2021 00000000000
CA-3212907-A1 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof Pending 26-Mar-2021 A61K47/6803
To view Bolt Biotherapeutics’s complete patent history, request access »

Bolt Biotherapeutics Executive Team (9)

Name Title Board Seat Contact Info
William Quinn Chief Financial Officer
Grant Yonehiro Executive
Karen Bergman Vice President, Communications and Investor Relations
Edith Perez MD Chief Medical Officer
Randall Schatzman Ph.D Chief Executive Officer & Board Member
You’re viewing 5 of 9 executive team members. Get the full list »

Bolt Biotherapeutics Board Members (14)

Name Representing Role Since
Ashish Khanna Ph.D Nan Fung Life Sciences Board Member 000 0000
Brian O'Callaghan Self Board Member 000 0000
Edgar Engleman MD Vivo Capital Board Member & Founder 000 0000
Frank Lee Self Board Member 000 0000
James Healy Ph.D Sofinnova Investments Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Bolt Biotherapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bolt Biotherapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Bolt Biotherapeutics‘s full profile, request access.

Request a free trial

Bolt Biotherapeutics ESG

Risk Overview

Risk Rating

Updated December, 06, 2022

31.6 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,638

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,008

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 473

Rank

00.00

Percentile

To view Bolt Biotherapeutics’s complete esg history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »